Novo Nordisk stock is showing exceptional strength. Why is NVO stock surging?
Novo Nordisk’s rally is landing in a market that’s increasingly focused on the downstream impact of GLP-1 adoption, including reports that users consume up to 21% fewer calories as appetite suppression reshapes consumer demand. That "less volume, more premium" dynamic is part of the users’ consumption-up narrative that can keep payer coverage and pharmacy support programs front and center for GLP‑1 leaders.Critical Support Levels for NVO StockTechnically, the stock is reclaiming shorter-term trend support: it’s trading about 5.2% above the 20-day SMA ($43.73), 6.8% above the 50-day SMA ($43.10), and 8% above the 100-day SMA ($42.62). The bigger hurdle is the long-term trend, with price still about 4.3% below the 200-day SMA ($48.10), which often acts like "gravity" on rallies until it’s cleared.Momentum looks improved: MACD is above its signal line and the histogram is positive, which typically means downside pressure is easing and the rebound is gaining traction versus the prior downswing. In plain terms, when MACD is above the signal line, it suggests buyers are starting to control the pace even if the longer-term trend hasn’t fully flipped.
